Core Viewpoint - Autonomix Medical, Inc. has successfully closed a public offering of common stock and pre-funded warrant units, raising approximately $10.0 million to support its clinical trials and research initiatives [1][3]. Group 1: Offering Details - The equity offering consisted of 615,500 common stock units and 917,596 pre-funded warrant units, priced at $6.54 and $6.539 per unit respectively [2]. - Each common stock unit and pre-funded warrant unit included one share of common stock and one Series A Warrant, which has an exercise price of $6.54 and expires five years from issuance [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for funding clinical trials, research and development, intellectual property development, and working capital [3]. Group 3: Company Overview - Autonomix Medical is focused on innovative technologies for diagnosing and treating diseases of the nervous system, featuring a catheter-based microchip sensing array with significantly enhanced sensitivity [6]. - The company is initially targeting pain management, particularly for pancreatic cancer, and aims to address various conditions across a wide disease spectrum [7].

THE WOODLANDS, TX, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the pricing of an underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $9.0 million prior to deducting underwriting discounts and commissions and offering expenses. The equity offering is comprised of 1,376,287 commo ...

[Form 8-K Current Report](index=1&type=section&id=Form%208-K) This current report details significant events, including financial results and related exhibits [Item 2.02. Results of Operations and Financial Condition](index=1&type=section&id=Item%202.02.%20Results%20of%20Operations%20and%20Financial%20Condition) Autonomix Medical, Inc. announced its financial results for the three and six months ended September 30, 2024, via a press release - The company announced financial results for the three and six months ended September 30, 2024[2](index=2&type=chunk) - The announcement was made through a press release dated November 11, 2024, attached as Exhibit 99.1 and incorporated by reference[2](index=2&type=chunk) [Item 9.01. Financial Statements and Exhibits](index=3&type=section&id=Item%209.01.%20Financial%20Statements%20and%20Exhibits) This section details the exhibits accompanying the Form 8-K report, primarily the press release with financial results | Exhibit No. | Exhibit Description | | :--- | :--- | | 99.1 | Press Release dated November 11, 2024 | | 104 | Cover page Interactive Data File (embedded within the Inline XBRL document) |

Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer; Preliminary results demonstrate 100% of the lead-in patient responder group went to zero opioid use at 4-6 weeks post-procedure Company’s first-in-class technology has demonstrated significant, enduring reduction in pain and improvement in quality of life in ongoing PoC study to date THE WOODLANDS, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical dev ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to__________ Commission file number 001-41940 Autonomix Medical, Inc. (Exact Name of Registrant as Specified in Its Charter) De ...

Access the Virtual Investor "What This Means" Segment here THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it recently participated in a Virtual Investor "What This Means" segment. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company's recently announced 4-6 week positive follow-up data, f ...

Autonomix Medical, Inc. (AMIX) shared positive preliminary results from its first five lead-in patients in a proof-of-concept trial. The trial assesses the safety and effectiveness of Autonomix's proprietary radiofrequency (RF) ablation technology, designed to ablate targeted nerves and reduce pain in late-stage pancreatic cancer patients. Among participants, three treated through femoral access experienced significant pain reduction — from a mean score of 8 to 1.33 on the Visual Analog Scale — and were abl ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 points on Monday.The Dow traded up 0.52% to 42,333.84 while the NASDAQ rose 0.43% to 18,598.02. The S&P 500 also rose, gaining, 0.31% to 5,826.12.Check This Out: How To Earn $500 A Month From Ford Stock Ahead Of Q3 EarningsLeading and Lagging SectorsUtilities shares rose by 1.1% on Monday.In trading on Monday, energy shares fell by 1%.Top HeadlineON Semiconductor Corp ON posted better-than-expected earnings for ...

Autonomix Medical, Inc. AMIX stock is trading higher on Monday, with a strong session volume of 6.11 million compared to the average volume of 22.87 thousand, as per data from Benzinga Pro. The nano-cap firm focused on developing technologies for the nervous system revealed preliminary results from the first five "lead-in" patients in the company's ongoing proof-of-concept human trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigat ...

THE WOODLANDS, TX, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing precision nervetargeted treatments, today announced that it will release a Virtual Investor "What This Means" segment on Wednesday, October 30, 2024. For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix will discuss additional findings from the 4-6 week follow-up data from the first five "lead-in" patients in the Company ...